Group One Trading’s Avidity Biosciences RNAM Stock Holding History

Group One Trading’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,700	Closed	-$1.78M	–	8570
2025 Q4	$1.78M	Sell	24,700 -700	-3%	-$45.2K	﹤0.01%	2385
2025 Q3	$1.11M	Buy	25,400 +23,300	+1,110%	+$942K	﹤0.01%	2920
2025 Q2	$59.6K	Sell	2,100 -25,500	-92%	-$760K	﹤0.01%	5431
2025 Q1	$815K	Buy	+27,600	New	+$860K	﹤0.01%	2639
2024 Q3	–	Sell	-800	Closed	-$32.7K	–	7261
2024 Q2	$32.7K	Buy	+800	New	+$23K	﹤0.01%	4852
2023 Q4	–	Sell	-500	Closed	-$3.19K	–	8077
2023 Q3	$3.19K	Sell	500 -16,500	-97%	-$142K	﹤0.01%	6892
2023 Q2	$189K	Buy	+17,000	New	+$213K	﹤0.01%	3996
2023 Q1	–	Sell	-3,700	Closed	-$82.1K	–	7844
2022 Q4	$82.1K	Buy	+3,700	New	+$55.2K	﹤0.01%	4605

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

Group One Trading's RNAM Position: Q1 2026 in Review

Group One Trading sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 18,571 shares — an estimated $1.34M sold.

Group One Trading first reported a position in RNAM in Q1 2023 and held it in 9 quarters. The position peaked at $1.71M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Group One Trading reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Group One Trading sold 18,571 Avidity Biosciences shares in Q1 2026, an estimated $1.34M.
Group One Trading first reported a position in Avidity Biosciences in Q1 2023 and held it in 9 quarters.
Group One Trading's Avidity Biosciences position peaked at $1.71M in Q3 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.